$CC

Chemours Co

CIK:0001627223|SEC Filings

Interim Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Millions

3 Months Ended

6 Months Ended

Jun. 30, 2026

Jun. 30, 2025

Jun. 30, 2026

Jun. 30, 2025

Income Statement [Abstract]

Net sales

$ 1,591

$ 1,615

$ 2,972

$ 2,983

Cost of goods sold

1,305

1,337

2,474

2,469

Gross profit

286

278

498

514

Selling, general, and administrative expense

469

424

616

547

Research and development expense

Restructuring, asset-related, and other charges

Total other operating expenses

499

470

685

653

Equity in earnings of affiliates

Interest expense, net

(68)

(67)

(137)

(133)

Loss on extinguishment of debt

(2)

(11)

Other income, net

273

296

Loss before income taxes

(1)

(248)

(22)

(249)

Provision for income taxes

273

131

281

135

Net loss

(274)

(379)

(303)

(384)

Less: Net income attributable to non-controlling interests

Net loss attributable to Chemours

$ (274)

$ (380)

$ (303)

$ (385)

Per share data

Basic (loss) earnings per share of common stock

^[1]

$ (1.81)

$ (2.53)

$ (2.01)

$ (2.56)

Diluted (loss) earnings per share of common stock

^[1],[2]

$ (1.81)

$ (2.53)

$ (2.01)

$ (2.56)

[1]

Figures may not recalculate exactly due to rounding. Basic and diluted earnings per share are calculated based on unrounded numbers.

[2]

In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS, as their inclusion would have an anti-dilutive effect. As such, with respect to the measure of diluted EPS, the impact of 1,588,513 and 1,204,120 potentially dilutive securities is excluded from the calculation for three and six months ended June 30, 2026, respectively. Additionally, with respect to the measure of diluted EPS, the impact of 268,070 and 379,632 potentially dilutive securities is excluded from the calculation for the three and six months ended June 30, 2025, respectively.

Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities
Net loss	$ (303)	$ (384)
Adjustments to reconcile net income to cash used for operating activities:
Depreciation and amortization	159	180
Gain on sales of assets and businesses	(266)	(1)
Equity in earnings of affiliates, net	(10)	(16)
Loss on extinguishment of debt	11	0
Amortization of debt issuance costs and issue discounts	5	6
Deferred tax provision	238	97
Asset-related charges	1	11
Stock-based compensation expense	14	12
Net periodic pension (income) cost	(1)
Defined benefit plan contributions	(1)	(8)
Other operating charges and credits, net	(9)	14
Decrease (increase) in operating assets:
Accounts and notes receivable, net	(218)	(174)
Inventories and other current operating assets	114	(42)
Other non-current operating assets	53	64
(Decrease) increase in operating liabilities:
Accounts payable	(12)	(87)
Other current operating liabilities	217	70
Other non-current operating liabilities	122	239
Cash provided by (used for) operating activities	114	(19)
Cash flows from investing activities
Purchases of property, plant, and equipment	(93)	(127)
Proceeds from life insurance policies	1
Proceeds from sales of assets and businesses	294	1
Foreign exchange contract settlements, net	(7)	(2)
Cash provided by (used for) investing activities	195	(128)
Cash flows from financing activities
Proceeds from issuance of debt	700	95
Debt repayments	(963)	(111)
Payments on finance leases	(5)	(7)
Payments of debt issuance cost	(10)	(4)
Proceeds from supplier financing program	32	47
Payments to supplier financing program	(31)	(53)
Proceeds from exercised stock options, net	3
Payments related to tax withholdings on vested stock awards	(2)	(1)
Payments of dividends to the Company's common shareholders	(26)	(50)
Debt extinguishment payments	(6)
Cash used for financing activities	(308)	(84)
Effect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash equivalents	(2)	21
Decrease in cash, cash equivalents, restricted cash and restricted cash equivalents	(1)	(210)
Cash, cash equivalents, restricted cash and restricted cash equivalents at January 1,	724	763
Cash, cash equivalents, restricted cash and restricted cash equivalents at June 30,	723	553
Non-cash investing and financing activities:
Purchases of property, plant, and equipment included in accounts payable	$ 26	$ 26

Interim Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 671	$ 670
Restricted cash and restricted cash equivalents	0	2
Accounts and notes receivable, net	907	679
Inventories	1,452	1,569
Prepaid expenses and other	63	80
Assets held for sale	1	1
Total current assets	3,094	3,001
Property, plant, and equipment	9,993	9,920
Less: Accumulated depreciation	(6,965)	(6,842)
Property, plant, and equipment, net	3,028	3,078
Operating lease right-of-use assets	270	271
Goodwill	46	46
Other intangible assets, net	2	2
Investments in affiliates	170	160
Assets held for sale, non-current	0	21
Restricted cash and restricted cash equivalents	52	52
Other assets	488	751
Total assets	7,150	7,382
Current liabilities:
Accounts payable	937	954
Compensation and other employee-related cost	83	96
Short-term and current maturities of long-term debt	34	42
Current environmental remediation	124	88
Other accrued liabilities	683	506
Total current liabilities	1,861	1,686
Long-term debt, net	3,838	4,099
Operating lease liabilities	191	191
Long-term environmental remediation	671	530
Deferred income taxes	64	37
Other liabilities	573	588
Total liabilities	7,198	7,131
Commitments and contingent liabilities
Equity
Common stock (par value $0.01 per share; 810,000,000 shares authorized; 199,276,562 shares issued and 150,463,268 shares outstanding at June 30, 2026; 198,720,786 shares issued and 149,893,993 shares outstanding at December 31, 2025)	2	2
Treasury stock, at cost (48,813,294 shares at June 30, 2026 and 48,826,793 at December 31, 2025)	(1,801)	(1,802)
Additional paid-in capital	1,088	1,074
Retained earnings	891	1,220
Accumulated other comprehensive loss	(229)	(244)
Total Chemours stockholders’ equity	(49)	250
Non-controlling interests	1	1
Total equity	(48)	251
Total liabilities and equity	$ 7,150	$ 7,382